BackTravere Therapeutics Overview

Travere Therapeutics Long Term Debt

Track Travere Therapeutics's long-term debt ($610M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$610.74M
↑ 87.84% YoYΔ $285.60M vs prior year quarter

Peer trimmed avg / median

Loading

Travere Therapeutics Long Term Debt History

Loading

Travere Therapeutics vs. peers: Long Term Debt Comparison

Loading

Travere Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Travere Therapeutics (TVTX) FAQ

As of the most recent data (June 2026), TVTX shows a long-term debt of $610M. That compares with $330M in the prior-year period — up 87.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TVTX's long-term debt is now $610M (was $330M) — a 87.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Travere Therapeutics is outperforming or lagging.

Tracking TVTX's long-term debt over time shows whether Travere Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $610M That compares with $330M in the prior-year period — up 87.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Travere Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $610M) with ownership activity and broader fundamentals.

Travere Therapeutics's long-term debt is $610M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.